South Korea: In a post hoc analysis of the randomized PULSAR trial, aflibercept 8 mg demonstrated noninferior visual outcomes ...

A recent post‑hoc analysis of the COMMANDS trial evaluated the benefits of Luspatercept versus Epoetin alfa (EA) in ESA‑naïve ...

Oral micronutrient supplementation showed no benefit on geographic atrophy lesion growth among a patient group from the OAKS and DERBY trials, according to a speaker ...

Nemolizumab, which targets the interleukin-31 pathway, rapidly improves itch and sleep in people with atopic dermatitis and ...

In a subgroup analysis of patients with polypoidal choroidal vasculopathy, aflibercept 8 mg achieved similar vision gains to ...

Baseline heart rate variability is a critical predictor of response to transcutaneous auricular vagus nerve stimulation, ...

New trial analysis shows COPD treatment withdrawal, including LAMA and ICS discontinuation, can trigger early exacerbation ...

Office and ambulatory BP improved, with minimal side effects, although some say edema needs to be watched carefully.

Starting an incretin receptor agonist -- especially tirzepatide (Mounjaro, Zepbound) -- was associated with reduced risks of ...

The prospective data indicate that clinicians should be aggressive with lipid-lowering therapies in these patients, experts say.

Traditional rule-based systems, once sufficient for detecting simple patterns of fraud, have been overwhelmed by the scale, ...

Once-weekly tirzepatide is associated with clinically relevant reductions in SUA levels over 72 weeks, largely driven by substantial weight loss.